Infection  /  Future Value

17 Matching Facts

Search matching Facts:
No results to display
    • Vaccines in development 2013
      Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
    • Vaccines in development 2013
      Vaccines in development for 2013  
    • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
      A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
    • Reduction in hospital-acquired HAIs could produce significant savings
      Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
    • Use of shingles vaccine could save $82 to $103 million
      Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
    • Potential savings from shingles vaccine
      Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
    • Shingles vaccine could improve QALY and save money
      Vaccination of 1 million people age 60 and over with the shingles vaccine would result in 11,919 non-discounted and 8,782 discounted QALYs (quality of life years) gained and save around…  
    • Potential cost effectiveness of shingles vaccines
      The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
    • Cost-effectiveness of flu vaccine
      Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.  
    • Economic value from flu vaccine in elderly
      As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest…  
    • Each flu case prevented could save $60 to $4,000
      The influenza vaccination could save between $60 and $4,000 per case prevented.  
    • Potential value of pneumonia vaccine
      Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
    • Shingles vaccine would reduce healthcare use
      Use of the shingles vaccine in immunocompetent adults could eliminate more than 300,000 outpatient visits, 375,000 prescriptions, 9,700 emergency room visits, and 10,000 hospitalizations.  
    • ~One-third of shingles death preventable with vaccine
      Approximately one-third of shingles deaths may be preventable through vaccination.  
    • Annual flu vaccine could save 275,000 QALYs
      Offering the influenza vaccine annually to all people over the age of 50 would save around 275,000 quality-adjusted life years over the lifetimes of a birth cohort of 4 million.…  
    • Flu vaccine use can reduce illness risk in U.S. by 60%
      Recent studies from the Centers for Disease Control and Prevention show that the influenza vaccine can reduce the risk of illness in the overall U.S. population by around 60%. …  
    • Vaccines in development 2013
      137 vaccines are currently in development in the U.S. for infectious diseases.